Products - Heart failure | Topic | NICE

Showing 19 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2023
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
24 January 2022
Published:
4 September 2019
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Patiromer for treating hyperkalaemia (TA623)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 February 2020
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2016
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2014
Ivabradine for treating chronic heart failure (TA267)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 November 2012
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 August 2025
Rivaroxaban for treating chronic heart failure [ID1462]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years TS ID 10350
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC